Paxil class action settlement
A Minnesota District Court judge on Sept. 28 approved a class action settlement under which GlaxoSmithKline will pay $40 million to reimburse third party payers for costs of Paxil (paroxetine) prescribed to persons under the age of 18. Plaintiffs claimed GSK promoted Paxil for children when clinical trials showed the antidepressant had a greater risk of suicide risk than placebo. Last year GSK settled a class action involving parents who sought reimbursement for Paxil prescriptions
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.